Top-Rated Dividend StocksTop-Rated DividendNYSE:ABT Abbott Laboratories (ABT) Stock Price, News & Analysis $103.38 -0.32 (-0.31%) As of 09:53 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Abbott Laboratories Stock (NYSE:ABT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abbott Laboratories alerts:Sign Up Key Stats Today's Range$102.90▼$104.3550-Day Range$96.62▼$116.7052-Week Range$81.97▼$132.02Volume190,685 shsAverage Volume11.27 million shsMarket Capitalization$178.88 billionP/E Ratio38.57Dividend Yield2.44%Price Target$118.32Consensus RatingModerate Buy Company Overview Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world. Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care. The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte. Robert B. Ford serves as Abbott’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Abbott Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreABT MarketRank™: 4.853556485355 of 5 starsAbbott Laboratories scored higher than 97% of companies evaluated by MarketBeat, and ranked 4th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingAbbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 2 strong buy ratings, 22 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialAbbott Laboratories has a consensus price target of $118.32, representing about 14.1% upside from its current price of $103.70.Amount of Analyst CoverageAbbott Laboratories has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Abbott Laboratories' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.79% Earnings GrowthEarnings for Abbott Laboratories are expected to grow by 7.79% in the coming year, from $5.52 to $5.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abbott Laboratories is 38.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Abbott Laboratories is 38.70, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.90.Price to Earnings Growth RatioAbbott Laboratories has a PEG Ratio of 1.82. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAbbott Laboratories has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.79% of the float of Abbott Laboratories has been sold short.Short Interest Ratio / Days to CoverAbbott Laboratories has a short interest ratio ("days to cover") of 1.46, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abbott Laboratories has recently decreased by 31.52%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAbbott Laboratories pays a meaningful dividend of 2.43%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAbbott Laboratories has been increasing its dividend for 54 years.Dividend CoverageThe dividend payout ratio of Abbott Laboratories is 94.03%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 42.35% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.Read more about Abbott Laboratories' dividend. News and Social Media3.3 / 5News Sentiment0.30 News SentimentAbbott Laboratories has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 102 news articles for Abbott Laboratories this week, compared to 10 articles on an average week.Search Interest47 people have searched for ABT on MarketBeat in the last 30 days. This is an increase of 2% compared to the previous 30 days.MarketBeat Follows30 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Abbott Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,958.00 in company stock.Percentage Held by Insiders0.46% of the stock of Abbott Laboratories is held by insiders.Percentage Held by Institutions75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abbott Laboratories' insider trading history. Receive ABT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABT Stock News HeadlinesAbbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment40 minutes ago | prnewswire.comAbbott Laboratories: A New Growth Story Takes Shape1 hour ago | seekingalpha.comBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A free digital guide breaks down the basics of Gold IRAs in plain language. Inside: the top 5 advantages of a Gold IRA, how to move a 401k penalty free, why diversification matters, and a simple checklist to get started. Qualified orders of $50,000 or more may also receive bonus silver, while supplies last.October 26 at 1:00 AM | Goldco Direct, LLC (Ad)Abbott Laboratories (ABT) - What Are Brokerages Saying About This Stock?October 26 at 2:31 AM | americanbankingnews.comMarketBeat Week in Review – 10/19 - 10/23 (ABT)A market sell-off spread beyond tech as oil prices surged and AI concerns grew. MarketBeat analysts recap the week's top stories on earnings, from Halliburton to Meta Platforms and General Motors.October 24 at 7:00 AM | marketbeat.com3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach (ABT)Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.October 23 at 7:25 AM | marketbeat.comCologuard Is Working—So Why Isn’t Abbott Stock?Abbott's stock fell 4% despite solid Q3 results, as it trimmed full-year sales guidance and announced plans to spin off its Nutrition business into a separate public company by 2027.October 22, 2026 | marketbeat.comCologuard Is Working—So Why Isn’t Abbott Stock?Abbott's stock fell 4% despite solid Q3 results, as it trimmed full-year sales guidance and announced plans to spin off its Nutrition business into a separate public company by 2027.October 22, 2026 | marketbeat.comSee More Headlines ABT Stock Analysis - Frequently Asked Questions How have ABT shares performed this year? Abbott Laboratories' stock was trading at $125.30 at the beginning of the year. Since then, ABT shares have decreased by 17.2% and is now trading at $103.7030. How were Abbott Laboratories' earnings last quarter? Abbott Laboratories (NYSE:ABT) posted its quarterly earnings results on Wednesday, October, 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting the consensus estimate of $1.42. The business's revenue for the quarter was up 14.5% on a year-over-year basis. Read the conference call transcript. Does Abbott Laboratories have any subsidiaries? Abbott Laboratories subsidiaries include these companies: Cephea Valve Technologies, Alere, St. Jude Medical, Kalila Medical, Tendyne Holdings Inc., Veropharm, Topera Inc., and more. Who are Abbott Laboratories' major shareholders? Abbott Laboratories' top institutional shareholders include Assenagon Asset Management S.A. (0.30%), Ninety One UK Ltd (0.10%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.09%) and Sepio Capital LP (0.05%). Insiders that own company stock include Daniel J Starks, Robert B Ford, Jr Robert E Funck, Jr Robert E Funck, Daniel Gesua Sive Salvadori, Mary K Moreland, Andrea F Wainer, Lisa D Earnhardt, Eric Shroff, Elizabeth C Cushman, John A Jr Mccoy and Philip P Boudreau. View institutional ownership trends. How do I buy shares of Abbott Laboratories? Shares of ABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abbott Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abbott Laboratories investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Walmart (WMT), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD). Company Calendar Record date for 8/17 Dividend7/15/2026Ex-Dividend for 8/17 Dividend7/15/2026Dividend Payable8/17/2026Record date for 11/16 Dividend10/15/2026Ex-Dividend for 11/16 Dividend10/15/2026Last Earnings10/21/2026Today10/26/2026Dividend Payable11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, ABT's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:ABT CIK1800 Webwww.abbott.com Phone(224) 667-6100Fax847-937-1511Employees115,000Year Founded1888Price Target and Rating Average Price Target for Abbott Laboratories$118.32 High Price Target$135.00 Low Price Target$92.00 Potential Upside/Downside+14.5%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage28 Analysts Profitability EPS (Trailing Twelve Months)$2.68 Trailing P/E Ratio38.70 Forward P/E Ratio18.72 P/E Growth1.82Net Income$6.52 billion Net Margins9.75% Pretax Margin13.61% Return on Equity17.97% Return on Assets9.22% Debt Debt-to-Equity Ratio0.57 Current Ratio1.38 Quick Ratio0.97 Sales & Book Value Annual Sales$44.33 billion Price / Sales4.03 Cash Flow$6.97 per share Price / Cash Flow14.83 Book Value$30.35 per share Price / Book3.40Miscellaneous Outstanding Shares1,730,380,000Free Float1,722,423,000Market Cap$178.80 billion OptionableOptionable Beta0.59 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NYSE:ABT) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredReport: OCC clears Trump-linked bankLast month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredForget the AI predictions. Look at the incomeAI predictions are everywhere, but Tim Plaehn is focused on something concrete: income. He's found a small ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abbott Laboratories Please log in to your account or sign up in order to add this asset to your watchlist. Share Abbott Laboratories With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
